Summer 2027

Operations Graduate Program Intern

Operations

Posted on 9/2/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$35.34 - $41.83/hr

No H1B Sponsorship

Remote in USA + 5 more

More locations: Cambridge, MA, USA | Thousand Oaks, CA, USA | Holly Springs, NC, USA | New Albany, OH, USA | West Greenwich, RI, USA

Remote

Includes an in-person week at Amgen headquarters in Thousand Oaks, California.

Bachelor's, Master's, MBA, PharmD, PhD

Category
Product (1)
Required Skills
Computer Networking

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Must be at least 18 years old.
  • Must have graduated with a bachelor's degree from an accredited college or university.
  • Must be currently enrolled in an accredited MBA, master's, PharmD, or PhD program and have completed the first year before the internship starts.
  • Must be available to work a full-time schedule.
  • Must remain enrolled following the internship or co-op.
  • Must be located in the United States for the duration of the internship.
  • Must be available to accept and commit to future full-time employment by July 2028 if offered.
Responsibilities
  • Complete an approximately 13-week internship project within the Operations function.
  • Explore opportunities and advance core business priorities.
  • Solve real organizational challenges and develop skills for future career success.
  • Participate in mentoring, coaching, experiential learning, virtual presentations, networking engagements, training sessions, one-on-one mentoring, and networking events.
Desired Qualifications
  • A bachelor's degree in science, engineering, or another relevant discipline.
  • Two years of relevant work experience in leadership, biotechnology or pharmaceuticals, consulting, engineering, healthcare, manufacturing, technology, or another relevant industry.
  • Experience applying artificial intelligence and continuous improvement techniques to automate processes and drive proactive problem-solving in continuous improvement contexts.
  • A passion for innovation in Operations.
  • Problem-solving, high-level critical-thinking, and strong analytical skills.
  • Strong business acumen, including the ability to understand business priorities and connect work to strategic objectives.
  • Intellectual curiosity, a growth mindset, and the ability to quickly learn from experiences and apply learnings to new or challenging situations.
  • Excellent interpersonal and networking skills.
  • Strong oral and written communication skills.
  • Strong time and project-management skills.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10%, and management raised full-year guidance again.
  • Repatha sales jumped 37% in Q2 2026 on stronger cardiology and primary-care demand.
  • Amgen approved IMDYLLTRA in Europe and opened a 2027 Hyderabad innovation center.

What critics are saying

  • FDA scrutiny threatens Tavneos withdrawal after the NEJM retraction and data-alteration probe.
  • Prolia sales fell 32% in Q2 2026 as biosimilar competition intensifies.
  • MariTide failure would leave Amgen dependent on aging brands and biosimilars after 2027.

What makes Amgen unique

  • Amgen sells multiple billion-dollar medicines, reducing dependence on any single franchise.
  • Repatha now shows hard cardiovascular mortality benefit, strengthening payer and physician adoption.
  • MariTide's monthly dosing targets a convenience gap versus weekly GLP-1 incumbents.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.